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Quantitative Ultrasound (QUS) is a non-invasive adjunct 
tool applied to the appendicular skeleton for diagnosing 
osteoporosis and identifying fracture risk (FDA, 1998). 
Dual-energy X-ray absorptiometry (DXA) remains the 
‘gold-standard’ for assessment of at-risk populations such 
as postmenopausal women, particularly in the absence of 
clinically evident fractures (Nelson 2002). However, interest 
persists in ultrasound techniques because they: are cheap, 
portable, and non-ionising; predict fractures and; correlate 
moderately with the findings of DXA. The most widely used 
system employs gel-coupling of twinned transducers to the 
medial and lateral calcaneus. This bone is weightbearing, 
has a high trabecular content, and is metabolically sensitive 
to systemic effects on the skeleton of ageing, nutrition, 
physical activity, disease, or therapy (Vogel 1988).
The theoretical basis of QUS is the variation in the speed of 
the ultrasound wave (SOS, in units of m/s) and its attenuation 
along its transmission path, at frequencies between 0.4 
and 1.0 MHz. Ultrasound waves travel faster in bone with 
higher density. In addition, as ultrasound passes through 
bone, it undergoes attenuation, with a consequent loss of 
transmitted acoustic energy. The slope of attenuation as a 
function of frequency (the broadband ultrasound attenuation 
[BUA], in units of dB/MHz) is lower in more porous and 
less microstructurally intact bone.
Aside from SOS and BUA, the most common derived 
variable is ‘stiffness’, a linear combination of SOS and 
BUA. Collectively these indices indirectly describe bone 
microarchitectural features such as trabecular spacing, 
orientation, and connectivity as well as density. However 
unlike DXA, QUS does not directly measure bone mineral 
density (BMD). 
Precision: Precision expressed as the standardised coefficient 
of variation ranges from 2.8% to 6.9% for BUA, and 4.3% 
to 8.4% for SOS (Njeh 2000). This is generally inferior to 
DXA and compromises longitudinal measurements of QUS 
(eg, charting treatment response), but has less effect on 
cross-sectional measurements (eg, predicting risk of future 
fractures).
Validity: Associations between calcaneal QUS and BMD: 
Weak to moderate associations are observed between QUS 
and DXA, with correlation coefficients ranging from 0.20 
to 0.64, indicating that calcaneal QUS has little value in 
predicting DXA BMD. This may be due to the effect of 
skeletal heterogeneity on bone mass and that QUS and 
DXA in part address different bone properties (Njeh 2001). 
Predicting fractures: Prospective epidemiological studies 
have shown that calcaneal QUS can predict hip fractures in 
elderly women as effectively as DXA BMD (Schott 2004). 
A recent meta-analysis of prospective studies concludes 
that QUS is generally a valid predictor of fracture risk at 
non-spinal sites (Marin 2006).
QUS as an adjunctive modality for estimating bone fragility 
is gaining recognition; however, it is still not widely 
accepted for the assessment of fracture risk, mainly due 
to the diversity of QUS devices and measurement sites, 
and lack of standardisation of thresholds of risk. Current 
diagnostic thresholds defined by the WHO (1994) and 
based on the T-score concept cannot validly be extended 
to QUS. Despite these limitations, QUS has been shown 
in prospective studies to be valid in predicting non-spinal 
fractures (Marin 2006); the inclusion of other clinical risk 
factors such as age and history of fracture, further increases 
the predictive power (Diez-Perez 2007).
There would be merit in focusing on calcaneal QUS because 
of its supporting clinical literature and its superior precision. 
QUS has several operational advantages over DXA; it is 
1) non-ionising; 2) portable and relatively inexpensive, 
and; 3) influenced by aspects of bone strength such as 
microstructure not addressed by DXA. However the most 
cost-effective use of QUS may be as an adjunct to DXA 
in preliminary assessment. A recent study reported that 
the use of QUS as a pre-screening modality followed by 
DXA assessment for those with low QUS readings incurred 
lower costs and would prevent more hip fractures than DXA 
alone (Kraemer 2006). The role of QUS in management 
of the patient following diagnosis is more problematic. 
The relatively poor long-term precision and restriction to 
appendicular sites reduces its power to reflect treatment-
induced changes at sites of clinical interest. Therefore 
it is likely that DXA will maintain its central role in the 
management of osteoporosis treatment and in the ongoing 
assessment of the untreated patient.
As the average age of Australians increases, fracture-risk 
assessments in primary health care and community settings 
(eg, in pharmacies) will increase. Clinicians should be 
aware of the potential role of QUS, particularly its possible 
synergistic role with DXA in initial assessment, as well as 
its proven capacity to predict hip fractures in the elderly.
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